In-depth analysis’ is a strategic and action-oriented analysis of the information available on Europe’s illicit drug markets. It takes a broad view of these markets from production and trafficking, to distribution and use. It provides a holistic and systemic perspective, capturing key aspects of the wider security and public health consequences of drug markets, as well as the main factors driving change and new threats (EMCDDA)
Bibliography: Economics
Focused Policy Assessment of Reducing Harm, Supporting Recovery
An analysis of expenditure and performance in the area of drug and alcohol misuse (Government of Ireland)
BC legal cannabis sales grow briskly: report
Cannabis products in BC are getting cheaper and more potent, and its year-over-year sales have doubled between 2019 and 2020, according to a new report from the Canadian Institute for Substance Use Research (CISUR)
Parents with alcohol and drug problems: using case studies to estimate the cost-benefit of interventions
This guidance supports local areas, organisations and providers that have collected, or intend to collect, case studies to estimate how much social and economic cost they can avoid by supporting families experiencing alcohol and drug problems (Public Health England)
Low-THC cannabis products in Europe
An increase in the open sale of cannabis products in Europe has raised questions around the possible legal and commercial status of these products – download (EMCDDA)
Western Hemisphere Drug Policy Commission report
The Western Hemisphere Drug Policy Commission is an independent, bipartisan entity with a two-fold mission: evaluate a range of US counternarcotics programs in the Americas and then make recommendations to improve them
Seizures of drugs in England and Wales, financial year ending 2020
Contains figures for seizures of drugs made by local police forces and the UK Border Force (Home Office)
Notes on Criminal Economics
Addresses an important but often overlooked issue: the way the proceeds from criminal activity interact with the national economic model, and vice versa (GDPO)
Drug Policy and the Development Fallacy
Contemporary debates surrounding drug policy and illicit cultivation have adopted a modern and flawed interpretation of ‘development’ (GDPO)
Recreational cannabis regulation and harm reduction
BERL advice to the Ministry of Justice (New Zealand)
Canadian Substance Use Costs and Harms (2015-2017)
This report provides a summary of key findings about the costs and harms of substance use in Canada from 2015 to 2017 (CCSA)
Highlights from the EU Drug Markets Report for policy and practice
This short publication presents the main highlights from the EU Drug Markets Report 2019, targeting policy and practice (EMCDDA)
EU Drug Markets Report 2019
The EU Drug Markets Report 2019 is the third comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol.
Economic Impact of Non-Medical Opioid Use in the United States
This study estimates the total economic burden of the opioid crisis in the United States from 2015 through 2018 and projects future costs of the opioid epidemic for 2019 (Society of Actuaries)
Road to Recovery (PDF)
Addiction in our society – the case for reform (Centre for Social Justice)
What America’s Users Spend on Illegal Drugs, 2006–2016
This report updates and extends estimates of the number of users, retail expenditures, and amount consumed from 2006 to 2016 for cocaine (including crack), heroin, marijuana, and methamphetamine in the United States, based on a methodology developed by the RAND Corporation for the Office of National Drug Control Policy
The cost and consequences of the war on drugs (PDF)
The report’s findings suggest that, from a human rights perspective, there must be a shift from international drug policies that focus on criminalization and supply reduction, to ones that have human rights and health at their core (Human Rights Foundation)
Denying Revenue or Wasting Money?
Assessing the Impact of the Air Campaign Against ‘Drugs Labs’ in Afghanistan (LSE)
EMCDDA Budget 2019
The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre’s Director to the Management Board, which may modify the draft before adopting it and submitting it to the European Commission. The Commission, in turn, makes its recommendations (which may again alter the draft) and presents the result to the European Council and Parliament. Download
The European Cannabis Report™ 4th Edition
examines: Commercial and business opportunities in 33 European markets – Changing legislation and new regulatory guidelines across the region – Emerging trends, market forecasts and industry insights (Prohibition Partners)